Erratum: Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: An endocrine society clinical practice guideline (The Journal of Clinical Endocrinology and Metabolism (2019) 104:9 (3939-3985) DOI: 10.1210/jc.2019-01338)

J. L. Rosenzweig, G. L. Bakris, L. F. Berglund, M. F. Hivert, E. S. Horton, R. R. Kalyani, M. H. Murad, B. L. Vergès

Research output: Contribution to journalComment/debatepeer-review

Abstract

The above-mentioned guideline by Rosenzweig JL, Ferrannini E, Grundy SM, Haffner SM, Heine RJ, Horton ES, and Kawamori R (J Clin Endo Metab. 2008;93(10): 3671–3689; doi: 10.1210/jc.2008-0222) was retired and replaced by the following publication: Rosenzweig JL, Bakris GL, Berglund LF, Hivert M-F, Horton ES, Kalyani RR, Murad MH, Vergès BL. Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline. J Clin Endo Metab. 2019;104(9): 3939–3985; doi: 10.1210/jc.2019-01338 doi: 10.1210/jc.2008-0222.

Original languageEnglish (US)
Pages (from-to)E2847
JournalJournal of Clinical Endocrinology and Metabolism
Volume106
Issue number7
DOIs
StatePublished - Jul 1 2021

ASJC Scopus subject areas

  • Biochemistry, medical
  • Endocrinology
  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology, Diabetes and Metabolism

Fingerprint

Dive into the research topics of 'Erratum: Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: An endocrine society clinical practice guideline (The Journal of Clinical Endocrinology and Metabolism (2019) 104:9 (3939-3985) DOI: 10.1210/jc.2019-01338)'. Together they form a unique fingerprint.

Cite this